Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The effects of erythropoietin on depressive symptoms and neurocognitive deficits
2008-004857-14Phase 2Completed
- Sponsor
- Psykiatrisk Center Rigshospitalet
- Start
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of erythropoietin in treatment-resistant depression (TRD), bipolar disorder (BD) and major depressive disorder (MDD), sponsored by Psykiatrisk Center Rigshospitalet. Primary endpoints: Change in depressive symptoms (Sub-study 1), Change in neurocognitive function (Sub-study 1) and 1 more. Started Apr 2009; status: completed.
02
Drugs
erythropoietin
03
Conditions
treatment-resistant depression (TRD)bipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-004857-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004857-14.